2011
DOI: 10.1016/s1567-5688(11)70367-1
|View full text |Cite
|
Sign up to set email alerts
|

366 the Novel Spleen Tyrosin Kinase Inhibitor Fostamatinib Disodium Attenuates Inflammation and Atherogenesis in Low Density Lipoprotein Receptor Deficient Mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2013
2013

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Orally administered fostamatinib, a recently developed Syk inhibitor, reduced atherosclerosis in LDLR-deficient mice by as much as 58% (767). Both endothelial inflammation and monocyte migration were inhibited.…”
Section: Canonical Nf-b Signaling Through the Cbm Complexmentioning
confidence: 99%
“…Orally administered fostamatinib, a recently developed Syk inhibitor, reduced atherosclerosis in LDLR-deficient mice by as much as 58% (767). Both endothelial inflammation and monocyte migration were inhibited.…”
Section: Canonical Nf-b Signaling Through the Cbm Complexmentioning
confidence: 99%